Correlation between microtubule-associated gene expression and chemosensitivity of patients with stage II non-small cell lung cancer

Abstract

The aim of this study was to explore the correlation between mRNA expression of β-tubulin-III and stathmin in patients with stage II non-small cell lung cancer (NSCLC) and the chemosensitivity to Navelbine plus cisplatin (NP), as well as to provide a basis for personalized treatment. A single-gene quantitative test was performed to detect the mRNA expression of β-tubulin-III and stathmin in the tumor tissue of patients with stage II NSCLC. All the patients underwent NP treatment following surgery and were followed-up to record their disease-free survival (DFS) and overall survival (OS). Statistical analyses were conducted to investigate the correlation between β-tubulin-III and stathmin mRNA expression and DFS and OS in the patients. β-tubulin-III mRNA expression was associated with OS in the 73 patients (P=0.003) and DFS was correlated with β-tubulin-III mRNA expression and lymphatic metastasis (P<0.01). Stathmin mRNA expression was not correlated with OS or DFS (P>0.05). OS and DFS were longer in the patients with low β-tubulin-III mRNA expression than in those with high β-tubulin-III mRNA expression (P<0.01); there was no significant change in OS and DFS between the patients with high and low mRNA expression of stathmin (P>0.05). The mRNA expression levels of β-tubulin-III in the tumor tissue of patients with stage II NSCLC may be considered as an index of prognosis and chemosensitivity, as well as a reference for personalized chemotherapeutic applications in patients.

The prognostic value and therapeutic target role of stathmin-1 in urinary bladder cancer

“…Concerning therapy prediction, not only taxane but also cisplatinresponse has been suggested to correlate to levels of STMN1 ( Singer et al , 2007 ; Belletti and Baldassarre, 2011 ). However, we could not validate the association between low STMN1 levels and increased cisplatin sensitivity in muscle-invasive bladder cancer, which is in concordance with the results in a lung cancer study ( Jiang et al , 2013 ).…”

The Prognostic Role of the Class III β-Tubulin in Non-Small Cell Lung Cancer (NSCLC) Patients Receiving the Taxane/Vinorebine-Based Chemotherapy: A Meta-Analysis

“…In the subgroup analysis by chemotherapy regimen, ten studies investigated the taxane-based regimens [19], [21]–[23], [25], [26], [30], [31], [35], [53]; four reported the vinorebine-based regimens [17], [20], [32], [33]; and four studies examined both regimens [27]–[29], [34]. The results of our analysis showed that the negative or low TUBB3 expression was associated with a longer OS than the positive or high TUBB3 expression in NSCLC patients receiving the taxane-based, or vinorebine-based, or both taxane- and vinorebine-based regimens (taxane regimen: HR = 2.06, 95% CI = 1.57–2.72, p <0.001; I 2  = 0.0%, P = 0.71 for heterogeneity; vinorebine regimen: HR = 1.45, 95% CI = 1.17–1.79, p  = 0.001; I 2  = 37.6%, P = 0.19 for heterogeneity; taxane and vinorebine combined regimen: HR = 1.19, 95% CI = 1.01–1.41, p  = 0.038; I 2  = 39.4%, P = 0.18 for heterogeneity, Table 2).…”

“…There were 9 studies conducted in the Caucasian population [16] – [20] , [27] – [30] ; 19 studies were conducted in the Asian population [21] – [26] , [31] – [43] ; and two studies were conducted in multiple ethnicities. Several methods were used to assess the expression of TUBB3: immunohistochemistry (IHC) in 25 studies [16] – [30] , [32] – [34] , [36] – [42] , polymerase chain reaction (PCR) in two studies [16] , [32] , and Western blot in one study [36] ( Table 1 ). All relevant studies were assessed by the NOS quality scale and all eligible studies scored highly (with five stars or more).…”

High TUBB2A expression in childhood T‐ALL is correlated with the clinical outcome

“…Altered expression of TUBB isotypes has been shown in a number of cancer types, which in turn may affect disease progression and response to therapy: High expression of tubulin βI in breast cancer is correlated with poor response to docetaxel 33 ; low βII in breast and ovarian cancers correlates with poor response to taxane 34,35 ; high βIII in non–small‐cell lung cancer (NSCLC) correlates with subtype and poor survival, poor response to taxane in breast cancer, poor survival in ovarian cancer and uterine serous carcinoma, poor response to taxane in gastric cancer and advanced disease, and early recurrence in prostate cancer 36‐39 ; high βIVa correlates with poor response to taxol in ovarian cancer 40 ; and high βV correlates with favorable response to taxane in NSCLC 41 . Alternative splicing and expression of Class II Tubulin Beta ( TUBB2B ) are also associated with outcome in diffuse large B‐cell lymphoma 42 .…”